Cortazar P, Zhang L, Untch M, Mehta K, Costantino JP, Wolmark N, Bonnefoi H, Cameron D, Gianni L, Valagussa P, Swain SM, Prowell T, Loibl S, Wickerham DL, Bogaerts J, Baselga J, Perou C, Blumenthal G, Blohmer J, Mamounas EP, Bergh J, Semiglazov V, Justice R, Eidtmann H, Paik S, Piccart M, Sridhara R, Fasching PA, Slaets L, Tang S, Gerber B, Geyer CE Jr, Pazdur R, Ditsch N, Rastogi P, Eiermann W, von Minckwitz G (2014) Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet 384(9938):164–172. https://doi.org/10.1016/S0140-6736(13)62422-8

Article  PubMed  Google Scholar 

Spring LM, Fell G, Arfe A, Sharma C, Greenup R, Reynolds KL, Smith BL, Alexander B, Moy B, Isakoff SJ, Parmigiani G, Trippa L, Bardia A (2020) Pathologic complete response after neoadjuvant chemotherapy and impact on breast Cancer recurrence and survival: a Comprehensive Meta-analysis. Clin Cancer Res 26(12):2838–2848. https://doi.org/10.1158/1078-0432.CCR-19-3492

Article  PubMed  PubMed Central  Google Scholar 

Huang M, O’Shaughnessy J, Zhao J, Haiderali A, Cortes J, Ramsey SD, Briggs A, Hu P, Karantza V, Aktan G, Qi CZ, Gu C, Xie J, Yuan M, Cook J, Untch M, Schmid P, Fasching PA (2020) Association of Pathologic Complete response with long-term survival outcomes in Triple-Negative breast Cancer: a Meta-analysis. Cancer Res 80(24):5427–5434. https://doi.org/10.1158/0008-5472.CAN-20-1792

Article  CAS  PubMed  Google Scholar 

Symmans WF, Wei C, Gould R, Yu X, Zhang Y, Liu M, Walls A, Bousamra A, Ramineni M, Sinn B, Hunt K, Buchholz TA, Valero V, Buzdar AU, Yang W, Brewster AM, Moulder S, Pusztai L, Hatzis C, Hortobagyi GN (2017) Long-term prognostic risk after Neoadjuvant Chemotherapy Associated with residual Cancer burden and breast Cancer subtype. J Clin Oncol 35(10):1049–1060. https://doi.org/10.1200/JCO.2015.63.1010

Article  CAS  PubMed  PubMed Central  Google Scholar 

Symmans WF, Peintinger F, Hatzis C, Rajan R, Kuerer H, Valero V, Assad L, Poniecka A, Hennessy B, Green M, Buzdar AU, Singletary SE, Hortobagyi GN, Pusztai L (2007) Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. J Clin Oncol 25(28):4414–4422. https://doi.org/10.1200/JCO.2007.10.6823

Article  PubMed  Google Scholar 

Yau C, van der Noordaa M, Wei J, Osdoit M, Reyal F, Hamy A-S, Lae M, Martin M, del Monte M, Boughey JC, Gould R, Wesseling J, Steenbruggen T, van Seijen M, Sonke G, Edge S, Sammut S-J, Provenzano E, Abraham J, Hall P, Graham A, Mackintosh L, Cameron D, Wang A, Sharma P, Cole K, Pusztai L, Kim M-O, van ‘t Veer L, Esserman L, Symmans WF (2020) Abstract GS5-01: Residual cancer burden after neoadjuvant therapy and long-term survival outcomes in breast cancer: A multi-center pooled analysis. Cancer Research 80 (4 Supplement):GS5-01-GS05-01. doi:https://doi.org/10.1158/1538-7445.Sabcs19-gs5-01

Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y, Pietenpol JA (2011) Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest 121(7):2750–2767. https://doi.org/10.1172/JCI45014

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lehmann BD, Pietenpol JA (2014) Identification and use of biomarkers in treatment strategies for triple-negative breast cancer subtypes. J Pathol 232(2):142–150. https://doi.org/10.1002/path.4280

Article  PubMed  PubMed Central  Google Scholar 

Yu KD, Zhu R, Zhan M, Rodriguez AA, Yang W, Wong S, Makris A, Lehmann BD, Chen X, Mayer I, Pietenpol JA, Shao ZM, Symmans WF, Chang JC (2013) Identification of prognosis-relevant subgroups in patients with chemoresistant triple-negative breast cancer. Clin Cancer Res 19(10):2723–2733. https://doi.org/10.1158/1078-0432.CCR-12-2986

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lehmann BD, Jovanovic B, Chen X, Estrada MV, Johnson KN, Shyr Y, Moses HL, Sanders ME, Pietenpol JA (2016) Refinement of Triple-Negative breast Cancer Molecular Subtypes: implications for Neoadjuvant Chemotherapy Selection. PLoS ONE 11(6):e0157368. https://doi.org/10.1371/journal.pone.0157368

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hennessy BT, Gonzalez-Angulo AM, Stemke-Hale K, Gilcrease MZ, Krishnamurthy S, Lee JS, Fridlyand J, Sahin A, Agarwal R, Joy C, Liu W, Stivers D, Baggerly K, Carey M, Lluch A, Monteagudo C, He X, Weigman V, Fan C, Palazzo J, Hortobagyi GN, Nolden LK, Wang NJ, Valero V, Gray JW, Perou CM, Mills GB (2009) Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics. Cancer Res 69(10):4116–4124. https://doi.org/10.1158/0008-5472.CAN-08-3441

Article  CAS  PubMed  PubMed Central  Google Scholar 

Taube JH, Herschkowitz JI, Komurov K, Zhou AY, Gupta S, Yang J, Hartwell K, Onder TT, Gupta PB, Evans KW, Hollier BG, Ram PT, Lander ES, Rosen JM, Weinberg RA, Mani SA (2010) Core epithelial-to-mesenchymal transition interactome gene-expression signature is associated with claudin-low and metaplastic breast cancer subtypes. Proc Natl Acad Sci U S A 107(35):15449–15454. https://doi.org/10.1073/pnas.1004900107

Article  PubMed  PubMed Central  Google Scholar 

Prat A, Parker JS, Karginova O, Fan C, Livasy C, Herschkowitz JI, He X, Perou CM (2010) Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res 12(5):R68. https://doi.org/10.1186/bcr2635

Article  CAS  PubMed  PubMed Central  Google Scholar 

Paplomata E, O’Regan R (2014) The PI3K/AKT/mTOR pathway in breast cancer: targets, trials and biomarkers. Ther Adv Med Oncol 6(4):154–166. https://doi.org/10.1177/1758834014530023

Article  CAS  PubMed  PubMed Central  Google Scholar 

Coussy F, El Botty R, Lavigne M, Gu C, Fuhrmann L, Briaux A, de Koning L, Dahmani A, Montaudon E, Morisset L, Huguet L, Sourd L, Painsec P, Chateau-Joubert S, Larcher T, Vacher S, Melaabi S, Salomon AV, Marangoni E, Bieche I (2020) Combination of PI3K and MEK inhibitors yields durable remission in PDX models of PIK3CA-mutated metaplastic breast cancers. J Hematol Oncol 13(1):13. https://doi.org/10.1186/s13045-020-0846-y

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ortega MA, Fraile-Martinez O, Asunsolo A, Bujan J, Garcia-Honduvilla N, Coca S (2020) Signal Transduction Pathways in Breast Cancer: The Important Role of PI3K/Akt/mTOR. J Oncol 2020:9258396. doi:https://doi.org/10.1155/2020/9258396

Conley SJ, Gheordunescu E, Kakarala P, Newman B, Korkaya H, Heath AN, Clouthier SG, Wicha MS (2012) Antiangiogenic agents increase breast cancer stem cells via the generation of tumor hypoxia. Proc Natl Acad Sci U S A 109(8):2784–2789. https://doi.org/10.1073/pnas.1018866109

Article  PubMed  PubMed Central  Google Scholar 

Wargotz ES, Norris HJ (1989) Metaplastic carcinomas of the breast. I. Matrix-producing carcinoma. Hum Pathol 20(7):628–635. https://doi.org/10.1016/0046-8177(89)90149-4

Article  CAS  PubMed  Google Scholar 

Wargotz ES, Deos PH, Norris HJ (1989) Metaplastic carcinomas of the breast. II. Spindle cell carcinoma. Hum Pathol 20(8):732–740. https://doi.org/10.1016/0046-8177(89)90065-8

Article  CAS  PubMed  Google Scholar 

Wargotz ES, Norris HJ (1989) Metaplastic carcinomas of the breast. III. Carcinosarcoma Cancer 64(7):1490–1499. https://doi.org/10.1002/1097-0142(19891001)64:7<1490::aid-cncr2820640722>3.0.co;2-l

Article  CAS  PubMed  Google Scholar 

Wargotz ES, Norris HJ (1990) Metaplastic carcinomas of the breast. IV. Squamous cell carcinoma of ductal origin. Cancer 65(2):272–276. https://doi.org/10.1002/1097-0142(19900115)65:2<272::aid-cncr2820650215>3.0.co;2-6

Article  CAS  PubMed  Google Scholar 

Wargotz ES, Norris HJ (1990) Metaplastic carcinomas of the breast: V. Metaplastic carcinoma with osteoclastic giant cells. Hum Pathol 21(11):1142–1150. https://doi.org/10.1016/0046-8177(90)90151-t

Article  CAS  PubMed  Google Scholar 

Bellino R, Arisio R, D’Addato F, Attini R, Durando A, Danese S, Bertone E, Grio R, Massobrio M (2003) Metaplastic breast carcinoma: pathology and clinical outcome. Anticancer Res 23(1B):669–673

PubMed  Google Scholar 

Zhang Y, Toy KA, Kleer CG (2012) Metaplastic breast carcinomas are enriched in markers of tumor-initiating cells and epithelial to mesenchymal transition. Mod Pathol 25(2):178–184. https://doi.org/10.1038/modpathol.2011.167

Article  CAS  PubMed  Google Scholar 

Hennessy B, Giordano S, Broglio K, Hortobagyi GN, Valero V (2005) Sarcomatoid (metaplastic) carcinoma of the breast: the U.T. M.D. Anderson Cancer Center (MDACC) and SEER database experience. J Clin Oncol 23(16suppl):614–614. https://doi.org/10.1200/jco.2005.23.16_suppl.614

Article  Google Scholar 

Hennessy BT, Giordano S, Broglio K, Duan Z, Trent J, Buchholz TA, Babiera G, Hortobagyi GN, Valero V (2006) Biphasic metaplastic sarcomatoid carcinoma of the breast. Ann Oncol 17(4):605–613. https://doi.org/10.1093/annonc/mdl006

Article  CAS  PubMed  Google Scholar 

Bae SY, Lee SK, Koo MY, Hur SM, Choi MY, Cho DH, Kim S, Choe JH, Lee JE, Kim JH, Kim JS, Nam SJ, Yang JH (2011) The prognoses of metaplastic breast cancer patients compared to those of triple-negative breast cancer patients. Breast Cancer Res Treat 126(2):471–478. https://doi.org/10.1007/s10549-011-1359-8

Article  CAS  PubMed  Google Scholar 

Basho RK, Gilcrease M, Murthy RK, Helgason T, Karp DD, Meric-Bernstam F, Hess KR, Herbrich SM, Valero V, Albarracin C, Litton JK, Chavez-MacGregor M, Ibrahim NK, Murray JL 3rd, Koenig KB, Hong D, Subbiah V, Kurzrock R, Janku F, Moulder SL (2017) Targeting the PI3K/AKT/mTOR pathway for the treatment of Mesenchymal Triple-Negative breast Cancer: evidence from a phase 1 trial of mTOR inhibition in Combination with Liposomal Doxorubicin and Bevacizumab. JAMA Oncol 3(4):509–515. https://doi.org/10.1001/jamaoncol.2016.5281

Article  PubMed  Google Scholar 

Basho RK, Yam C, Gilcrease M, Murthy RK, Helgason T, Karp DD, Meric-Bernstam F, Hess KR, Valero V, Albarracin C, Litton JK, Chavez-MacGregor M, Hong D, Kurzrock R, Hortobagyi GN, Janku F, Moulder SL (2018) Comparative effectiveness of an mTOR-Based systemic therapy regimen in Advanced, Metaplastic and Nonmetaplastic Triple-Negative breast Cancer. Oncologist 23(11):1300–1309. https://doi.org/10.1634/theoncologist.2017-0498

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wolff AC, Hammond ME, Hicks DG, Dowsett M, McShane LM, Allison KH, Allred DC, Bartlett JM, Bilous M, Fitzgibbons P, Hanna W, Jenkins RB, Mangu PB, Paik S, Perez EA, Press MF, Spears PA, Vance GH, Viale G, Hayes DF, American Society of Clinical O, College of American P (2014) Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: american society of clinical Oncology/College of american pathologists clinical practice guideline update. Arch Pathol Lab Med 138(2):241–256. https://doi.org/10.5858/arpa.2013-0953-SA

Article  PubMed  Google Scholar 

Yam C, Yen EY, Chang JT, Bassett RL Jr, Alatrash G, Garber H, Huo L, Yang F, Philips AV, Ding QQ, Lim B, Ueno NT, Kannan K, Sun X, Sun B, Parra Cuentas ER, Symmans WF, White JB, Ravenberg E, Seth S, Guerriero JL, Rauch GM, Damodaran S, Litton JK, Wargo JA, Hortobagyi GN, Futreal A, Wistuba II, Sun R, Moulder SL, Mittendorf EA (2021) Immune phenotype and response to Neoadjuvant Therapy in Triple-Negative breast Cancer. Clin Cancer Res. https://doi.org/10.1158/1078-0432.CCR-21-0144

Article  PubMed  PubMed Central